updating data

docs/SymptomsCausedByDrugs/data/ProportionalReportingRatios/vaccines/137.json

@@ -1 +1 @@
-{"Acute febrile neutrophilic dermatosis": 18.82969268886989, "Acute graft versus host disease in skin": 11.475916850729137, "Acute myeloid leukaemia": 74.73891875752705, "Acute myeloid leukaemia recurrent": 311.6572599101515, "Acute myeloid leukaemia refractory": 316.805896993179, "Acute respiratory failure": 3.998907967458603, "Agranulocytosis": 3.956415070085957, "Anaemia": 6.562574264637725, "Aspergillus infection": 10.788052278201825, "Bacillus infection": 97.91668952419596, "Bacteraemia": 23.173383842655763, "Blast cell count increased": 75.60746659487052, "Bone marrow disorder": 18.209017773186428, "Bone marrow failure": 12.053733958989952, "Bradypnoea": 13.955491513341414, "Bronchopulmonary aspergillosis": 9.467144769669227, "COVID-19 pneumonia": 5.022562084400602, "Candida infection": 4.14091601393544, "Cardiomyopathy": 4.3059031483059576, "Chronic graft versus host disease": 12.588829711661024, "Clostridium difficile infection": 4.311910718609019, "Congenital aplasia": 18.07612677823669, "Cytomegalovirus infection reactivation": 8.56835259258077, "Cytopenia": 60.83267129884074, "Disease progression": 4.20052370793295, "Disease recurrence": 3.2231194505925878, "Drug resistance": 2.460042616203085, "Ejection fraction decreased": 2.48437801264004, "Epstein-Barr virus infection reactivation": 21.448494226992747, "Febrile neutropenia": 57.72506348179317, "Full blood count decreased": 4.470106748047323, "Fungaemia": 27.554173674062927, "Fungal infection": 8.864341881982472, "Gene mutation": 22.397063404129423, "Graft versus host disease": 7.677888281745559, "Graft versus host disease in skin": 13.551880321876038, "Granulocyte count decreased": 38.3197928802718, "Haematotoxicity": 45.96069004427152, "Haemodynamic instability": 9.609600102688969, "Haemoglobin decreased": 2.012720730019101, "Haemophagocytic lymphohistiocytosis": 14.078457478158864, "Hepatic failure": 2.084752138218937, "Hyperbilirubinaemia": 2.2584543690588026, "Infection": 5.6438588113847, "JC virus infection": 47.00734851353359, "Leukocytosis": 3.7453140505611313, "Leukopenia": 2.6178500018659685, "Lung infiltration": 3.9712134913622257, "Lymphocyte count decreased": 4.51923658288471, "Malignant neoplasm progression": 2.0528288742589726, "Meningitis": 11.329537963438954, "Minimal residual disease": 124.9021968373036, "Mucosal inflammation": 2.2990966643045407, "Multiple organ dysfunction syndrome": 4.130361469672551, "Myelodysplastic syndrome": 20.665504242509662, "Myelosuppression": 28.384324838937022, "Myocardial ischaemia": 4.443949324395582, "Neutropenia": 16.004329295193667, "Neutropenic colitis": 31.263827805238563, "Neutropenic sepsis": 38.46956013909756, "Neutrophil count decreased": 7.995821449336806, "Off label use": 4.277899569440795, "Pancytopenia": 12.151355792967754, "Photophobia": 2.110253887541604, "Platelet count decreased": 5.2840529728928205, "Pneumocystis jirovecii pneumonia": 4.810503632835713, "Pneumonia": 3.904417489215523, "Pneumonia fungal": 52.381814793976176, "Pneumonitis": 4.512906102551736, "Pneumothorax": 7.678725651460646, "Product use in unapproved indication": 2.0163403753643445, "Progressive multifocal leukoencephalopathy": 16.383356634562368, "Pseudomonal bacteraemia": 68.5374381551583, "Respiratory distress": 2.457462934831252, "Respiratory failure": 2.8077252696461543, "Respiratory tract infection": 2.3763094965132394, "Second primary malignancy": 5.261337700330448, "Sepsis": 6.071747332350092, "Septic shock": 9.87379374040063, "Serum ferritin increased": 13.399058781761836, "Splenomegaly": 6.040376250849704, "Staphylococcal bacteraemia": 21.238791734885112, "Staphylococcal sepsis": 16.212030770111898, "Stenotrophomonas infection": 33.18064330827153, "Systemic candida": 26.5420189444426, "Therapeutic product effect incomplete": 3.207622870808815, "Therapy non-responder": 2.1710539905432444, "Therapy partial responder": 8.661754146913392, "Thrombocytopenia": 10.11140272202312, "Tumour lysis syndrome": 72.42978168997577, "Unevaluable event": 2.290218840538167, "Venoocclusive liver disease": 14.185020840545617, "White blood cell count abnormal": 14.751921149380658, "White blood cell count decreased": 6.574248365810278}
+{"abortion spontaneous": 2.33, "abscess": 10.94, "adverse event": 2.38, "alanine aminotransferase increased": 4.41, "application site erythema": 3.32, "aspartate aminotransferase increased": 4.31, "ataxia": 3.85, "autoimmune hepatitis": 10.76, "autoimmune thyroiditis": 6.46, "cardiomyopathy": 4.42, "cellulitis": 4.37, "depressed mood": 2.49, "depression": 3.77, "device operational issue": 36.0, "drug delivery system malfunction": 10.9, "drug-induced liver injury": 2.16, "erysipelas": 5.77, "expanded disability status scale score increased": 183.97, "gait disturbance": 3.28, "gait inability": 2.35, "gamma-glutamyltransferase increased": 8.04, "hemiparesis": 2.89, "hemiplegia": 2.77, "hepatic enzyme increased": 3.31, "hepatic steatosis": 3.47, "hepatitis": 3.42, "hyperthyroidism": 2.76, "impaired healing": 2.61, "incorrect dose administered by device": 14.69, "influenza like illness": 4.66, "injection site abscess": 142.54, "injection site atrophy": 81.63, "injection site bruising": 8.85, "injection site cellulitis": 71.91, "injection site discolouration": 40.41, "injection site erythema": 5.4, "injection site haematoma": 3.03, "injection site haemorrhage": 7.82, "injection site induration": 14.68, "injection site infection": 64.42, "injection site inflammation": 2.67, "injection site mass": 12.34, "injection site necrosis": 236.22, "injection site nodule": 12.77, "injection site oedema": 4.44, "injection site pain": 2.98, "injection site rash": 7.18, "injection site reaction": 10.3, "injection site ulcer": 174.51, "jaundice": 2.66, "leukopenia": 3.33, "liver function test increased": 12.53, "lymphocyte count decreased": 6.11, "lymphopenia": 3.1, "maternal exposure during pregcy": 2.57, "mobility decreased": 3.14, "multiple sclerosis": 58.94, "multiple sclerosis relapse": 61.83, "muscle rigidity": 2.49, "muscle spasticity": 21.09, "muscular weakness": 2.92, "nephrotic syndrome": 4.32, "neuromyelitis optica spectrum disorder": 27.55, "optic neuritis": 14.45, "panniculitis": 19.9, "paralysis": 2.61, "paraparesis": 12.47, "product dose omission issue": 3.54, "proteinuria": 2.17, "psychotic disorder": 2.07, "raynaud's phenomenon": 5.64, "secondary progressive multiple sclerosis": 68.28, "sensory disturbance": 2.23, "skin necrosis": 31.21, "skin reaction": 5.08, "skin ulcer": 3.08, "thrombotic microangiopathy": 10.64, "transaminases increased": 3.98, "urinary incontinence": 2.01}